(UroToday.com) Prostate-specific membrane antigen (PSMA)-targeted imaging has rapidly gained interest and utilization in patients with prostate cancer. Recently, two approaches (68-Gallium and Piflufolastat F-18 [PYLARIFY, previously known as 18F-DCFPyL]) have gained FDA approval for prostate cancer patients with suspected recurrence based on elevated PSA. This is driven by a proven ability to better localize and determine the extent of recurrent disease, compared with conventional imaging approaches. Two trials, OSPREY and CONDOR, formed the basis of the approval of Piflufolastat F-18.